Dasatinib, an approved kinase inhibitor for patients with CML and Philadelphia-positive acute myelogenous leukemia (AML), indirectly inhibits CRKL phosphorylation and synergizes with ALK inhibitors to enhance anticancer activities against ALK-rearranged cells. The gene discussed is ALK; the disease is acute myeloid leukemia.